Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study

被引:39
作者
Oakeshott, Pippa [1 ]
Aghaizu, Adamma [1 ]
Reid, Fiona [1 ]
Howell-Jones, Rebecca [2 ]
Hay, Phillip E. [3 ]
Sadiq, S. Tariq [3 ]
Lacey, Charles J. [4 ]
Beddows, Simon [5 ]
Soldan, Kate [2 ]
机构
[1] Univ London, Div Populat Hlth Sci, London SW17 0RE, England
[2] Hlth Protect Agcy, HIV & STI Dept, London NW9 5EQ, England
[3] Dept Genitourinary Med, London, England
[4] Univ York, Hull York Med Sch, York YO10 5DD, N Yorkshire, England
[5] Hlth Protect Agcy, Virus Reference Dept, London, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2012年 / 344卷
基金
英国医学研究理事会;
关键词
YOUNG-WOMEN; NATURAL-HISTORY; CERVICAL-CANCER; HPV INFECTION; VACCINES; CYTOLOGY; TRIAL; AGE; PREVENTION; CHLAMYDIA;
D O I
10.1136/bmj.e4168
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate frequency and risk factors for prevalent, incident, and persistent carcinogenic human papillomavirus (HPV) in young women before the introduction of immunisation against HPV types 16 and 18 for schoolgirls. Design Cohort study Setting 20 London universities and further education colleges. Participants 2185 sexually active female students, mean age 21 years (range 16-27), 38% from ethnic minorities, who took part in the POPI (prevention of pelvic infection) chlamydia screening trial in 2004-08 and who provided duplicate, self taken vaginal swabs and completed questionnaires at baseline. At follow-up, a median of 16 months later, 821 women (38%) returned repeat vaginal swabs by post. In 2009-10, stored samples were tested for HPV. Results Samples from 404/2185 (18.5% (95% CI 16.9% to 20.2%)) of the cohort were positive for carcinogenic HPV at baseline, including 15.0% (327) positive for non-vaccine carcinogenic genotypes. Reporting two or more sexual partners in the previous year and concurrent Chlamydia trachomatis or bacterial vaginosis were independent risk factors for prevalent vaginal HPV infection. Infection with one or more new HPV types was found in 17.7% (145/821) of follow-up samples, giving an estimated annual incidence of carcinogenic HPV infection of 12.9% (95% CI 11.0% to 15.0%). Incident infection was more common in women reporting two or more partners in the previous year, aged<20, of black ethnicity, or with C trachomatis vaginosis at baseline. Multiple partners was the only independent risk factor for incident infection (adjusted relative risk 1.99 (95% CI 1.46 to 2.72)). Of 143 women with baseline carcinogenic HPV infection, 20 (14% (8.3% to 19.7%) had infection with the same carcinogenic HPV type(s) detected after 12-28 months. Of these women, 13 (65%) had redetected infection with HPV 16 or 18, and nine (45%) with non-vaccine carcinogenic HPV genotypes. Conclusion In the first UK cohort study of carcinogenic HPV in young women in the community, multiple sexual partners was an independent predictor of both prevalent and incident infection. Infection with non-vaccine carcinogenic genotypes was common. Although current HPV vaccines offer partial cross protection against some non-vaccine carcinogenic HPV types, immunised women will still need cervical screening.
引用
收藏
页数:10
相关论文
共 28 条
[1]   A review of human carcinogens-Part B: biological agents [J].
Bouvard, Veronique ;
Baan, Robert ;
Straif, Kurt ;
Grosse, Yann ;
Secretan, Beatrice ;
El Ghissassi, Fatiha ;
Benbrahim-Tallaa, Lamia ;
Guha, Neela ;
Freeman, Crystal ;
Galichet, Laurent ;
Cogliano, Vincent .
LANCET ONCOLOGY, 2009, 10 (04) :321-322
[2]   Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study [J].
Brabin, Loretta ;
Roberts, Stephen A. ;
Stretch, Rebecca ;
Baxter, David ;
Chambers, Gloria ;
Kitchener, Henry ;
McCann, Rosemary .
BRITISH MEDICAL JOURNAL, 2008, 336 (7652) :1056-1058
[3]   Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study [J].
Castle, Philip E. ;
Cecilia Rodriguez, Ana ;
Burk, Robert D. ;
Herrero, Rolando ;
Wacholder, Sholom ;
Alfaro, Mario ;
Morales, Jorge ;
Guillen, Diego ;
Sherman, Mark E. ;
Solomon, Diane ;
Schiffman, Mark .
BMJ-BRITISH MEDICAL JOURNAL, 2009, 339 :327
[4]   Modelling the impact of HPV vaccines on cervical cancer and screening programmes [J].
Garnett, Geoffrey P. ;
Kim, Jane J. ;
French, Katherine ;
Goldie, Sue J. .
VACCINE, 2006, 24 :178-186
[5]   Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study [J].
Giuliano, Anna R. ;
Lee, Ji-Hyun ;
Fulp, William ;
Villa, Luisa L. ;
Lazcano, Eduardo ;
Papenfuss, Mary R. ;
Abrahamsen, Martha ;
Salmeron, Jorge ;
Anic, Gabriella M. ;
Rollison, Dana E. ;
Smith, Danelle .
LANCET, 2011, 377 (9769) :932-940
[6]   Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial [J].
Harper, DM ;
Franco, EL ;
Wheeler, CM ;
Moscicki, AB ;
Romonowski, B ;
Roteli-Martins, CM ;
Jenkins, D ;
Schuind, A ;
Clemens, SAC ;
Dubin, G .
LANCET, 2006, 367 (9518) :1247-1255
[7]   Natural history of cervicovaginal papillomavirus infection in young women [J].
Ho, GYF ;
Bierman, R ;
Beardsley, L ;
Chang, CJ ;
Burk, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (07) :423-428
[8]   Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England [J].
Howell-Jones, R. ;
Bailey, A. ;
Beddows, S. ;
Sargent, A. ;
de Silva, N. ;
Wilson, G. ;
Anton, J. ;
Nichols, T. ;
Soldan, K. ;
Kitchener, H. .
BRITISH JOURNAL OF CANCER, 2010, 103 (02) :209-216
[9]  
Howell-Jones R, 2012, VACCINE IN PRESS
[10]   Incidence and Predictors of Human Papillomavirus-6,-11,-16, and-18 Infection in Young Norwegian Women [J].
Kim, Soyeon ;
Arduino, Jean Marie ;
Roberts, Christine C. ;
Marsico, Mark ;
Liaw, Kai-Li ;
Skjeldestad, Finn Egil .
SEXUALLY TRANSMITTED DISEASES, 2011, 38 (07) :587-597